UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:August 12,
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Mirum Pharmaceuticals Charts.
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Mirum Pharmaceuticals Charts.

Mirum Pharmaceuticals, Inc. News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Thursday 11 April 2024 (2 weeks ago) • Business Wire
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Tuesday 2 April 2024 (4 weeks ago) • Business Wire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Monday 25 March 2024 (1 month ago) • GlobeNewswire Inc.
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Thursday 14 March 2024 (1 month ago) • Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Saturday 9 March 2024 (2 months ago) • Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Wednesday 6 March 2024 (2 months ago) • Business Wire
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Friday 1 March 2024 (2 months ago) • Business Wire
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
Thursday 29 February 2024 (2 months ago) • Business Wire
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
Thursday 22 February 2024 (2 months ago) • Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Saturday 10 February 2024 (3 months ago) • Business Wire

More Mirum Pharmaceuticals, Inc. News Articles